Aethlon Medical宣布,其与North Immunology的合并交易完成后,原Aethlon股东将持有合并后实体约4.75%的股份,而North Immunology股东则持有剩余约95.25%的股份。这一比例分配反映了双方在交易中的相对估值。
Aethlon Medical宣布,其与North Immunology的合并交易完成后,原Aethlon股东将持有合并后实体约4.75%的股份,而North Immunology股东则持有剩余约95.25%的股份。这一比例分配反映了双方在交易中的相对估值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.